JP2016506963A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506963A5 JP2016506963A5 JP2015556109A JP2015556109A JP2016506963A5 JP 2016506963 A5 JP2016506963 A5 JP 2016506963A5 JP 2015556109 A JP2015556109 A JP 2015556109A JP 2015556109 A JP2015556109 A JP 2015556109A JP 2016506963 A5 JP2016506963 A5 JP 2016506963A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydropyridin
- oxo
- benzamide
- trifluoromethyl
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 t- butyl Chemical group 0.000 claims description 404
- 229910052736 halogen Inorganic materials 0.000 claims description 89
- 150000002367 halogens Chemical class 0.000 claims description 89
- 150000001875 compounds Chemical class 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 44
- 208000002193 Pain Diseases 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 27
- 125000002723 alicyclic group Chemical group 0.000 claims description 17
- 208000004296 neuralgia Diseases 0.000 claims description 14
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 10
- 229910052740 iodine Inorganic materials 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 208000021722 neuropathic pain Diseases 0.000 claims description 7
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims description 6
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- YXHMFJXQQXHKRO-UHFFFAOYSA-N 2-(4-fluoro-2-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound CC1=CC(F)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 YXHMFJXQQXHKRO-UHFFFAOYSA-N 0.000 claims description 5
- 206010065390 Inflammatory pain Diseases 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 210000005036 nerve Anatomy 0.000 claims description 5
- PRBIFBCFSMEHTE-UHFFFAOYSA-N 5-fluoro-n-(2-oxo-1h-pyridin-4-yl)-2-phenoxybenzamide Chemical compound C1=CNC(=O)C=C1NC(=O)C1=CC(F)=CC=C1OC1=CC=CC=C1 PRBIFBCFSMEHTE-UHFFFAOYSA-N 0.000 claims description 4
- 208000005890 Neuroma Diseases 0.000 claims description 4
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims description 4
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims description 4
- 208000005298 acute pain Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- IBHSESFTJVMJEA-UHFFFAOYSA-N 4-cyano-2-(4-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound COC1=CC(F)=CC=C1OC1=CC(C#N)=CC=C1C(=O)NC1=CC(=O)NC=C1 IBHSESFTJVMJEA-UHFFFAOYSA-N 0.000 claims description 3
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 claims description 3
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000003349 osteoarthritic effect Effects 0.000 claims description 3
- 201000005572 sensory peripheral neuropathy Diseases 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- 206010003497 Asphyxia Diseases 0.000 claims description 2
- 208000008035 Back Pain Diseases 0.000 claims description 2
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 206010021639 Incontinence Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 208000008765 Sciatica Diseases 0.000 claims description 2
- 208000010261 Small Fiber Neuropathy Diseases 0.000 claims description 2
- 206010073928 Small fibre neuropathy Diseases 0.000 claims description 2
- 238000011225 antiretroviral therapy Methods 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 210000000467 autonomic pathway Anatomy 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000017692 primary erythermalgia Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 230000036262 stenosis Effects 0.000 claims description 2
- 208000037804 stenosis Diseases 0.000 claims description 2
- 208000004371 toothache Diseases 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 210000003901 trigeminal nerve Anatomy 0.000 claims description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims 32
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 24
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 14
- PAMCRRDMORMCSM-UHFFFAOYSA-N n-(trifluoromethyl)benzamide Chemical compound FC(F)(F)NC(=O)C1=CC=CC=C1 PAMCRRDMORMCSM-UHFFFAOYSA-N 0.000 claims 10
- XNAAGHKLQDFJAV-UHFFFAOYSA-N 2-(4-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(1,1,2,2,2-pentafluoroethyl)benzamide Chemical compound COC1=CC(F)=CC=C1OC1=CC(C(F)(F)C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 XNAAGHKLQDFJAV-UHFFFAOYSA-N 0.000 claims 4
- CSKLRKQUNQCFCW-UHFFFAOYSA-N 4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound COC1=CC(F)=CC=C1OC1=CC(Cl)=C(Cl)C=C1C(=O)NC1=CC(=O)NC=C1 CSKLRKQUNQCFCW-UHFFFAOYSA-N 0.000 claims 4
- FZRXMWNNMIDCAX-UHFFFAOYSA-N 4-chloro-2-(4-fluoro-2-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound CC1=CC(F)=CC=C1OC1=CC(Cl)=CC=C1C(=O)NC1=CC(=O)NC=C1 FZRXMWNNMIDCAX-UHFFFAOYSA-N 0.000 claims 4
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 claims 4
- 208000004550 Postoperative Pain Diseases 0.000 claims 3
- JLOCNBNTRGBNSU-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound FC1=CC(F)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 JLOCNBNTRGBNSU-UHFFFAOYSA-N 0.000 claims 2
- GIJKDQHCVRCMIN-UHFFFAOYSA-N 2-(3-fluoro-4-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound C1=C(F)C(OC)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 GIJKDQHCVRCMIN-UHFFFAOYSA-N 0.000 claims 2
- JKAMBBDGLZFTHQ-UHFFFAOYSA-N 2-(4-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound COC1=CC(F)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 JKAMBBDGLZFTHQ-UHFFFAOYSA-N 0.000 claims 2
- UXNUHKSSUVUOKZ-UHFFFAOYSA-N 2-(4-fluoro-2-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethoxy)benzamide Chemical compound CC1=CC(F)=CC=C1OC1=CC=C(OC(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 UXNUHKSSUVUOKZ-UHFFFAOYSA-N 0.000 claims 2
- WGJBFMMLUYGFBM-UHFFFAOYSA-N 2-[(5-fluoro-2-hydroxyphenyl)methoxy]-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound OC1=CC=C(F)C=C1COC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 WGJBFMMLUYGFBM-UHFFFAOYSA-N 0.000 claims 2
- HAHBFCDZJMZPDT-UHFFFAOYSA-N 2-[4-fluoro-2-(hydroxymethyl)phenoxy]-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound OCC1=CC(F)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 HAHBFCDZJMZPDT-UHFFFAOYSA-N 0.000 claims 2
- WLRVZQGFKCYIOQ-UHFFFAOYSA-N 4-chloro-2-(2-chloro-4-fluorophenoxy)-5-fluoro-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound ClC1=CC(F)=CC=C1OC1=CC(Cl)=C(F)C=C1C(=O)NC1=CC(=O)NC=C1 WLRVZQGFKCYIOQ-UHFFFAOYSA-N 0.000 claims 2
- UUAIQHMLXPMLDV-UHFFFAOYSA-N 4-chloro-2-(4-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound COC1=CC(F)=CC=C1OC1=CC(Cl)=CC=C1C(=O)NC1=CC(=O)NC=C1 UUAIQHMLXPMLDV-UHFFFAOYSA-N 0.000 claims 2
- CKTPSKKTZVSXLI-UHFFFAOYSA-N 4-tert-butyl-n-(2-oxo-1h-pyridin-4-yl)-2-[6-(trifluoromethyl)pyridin-3-yl]oxybenzamide Chemical compound C=1C=C(C(F)(F)F)N=CC=1OC1=CC(C(C)(C)C)=CC=C1C(=O)NC=1C=CNC(=O)C=1 CKTPSKKTZVSXLI-UHFFFAOYSA-N 0.000 claims 2
- IDCLDFZOZFUTLI-UHFFFAOYSA-N 5-chloro-2-(4-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound COC1=CC(F)=CC=C1OC1=CC=C(Cl)C=C1C(=O)NC1=CC(=O)NC=C1 IDCLDFZOZFUTLI-UHFFFAOYSA-N 0.000 claims 2
- KYRYYQRTAJIXDA-UHFFFAOYSA-N 5-fluoro-n-(2-oxo-1h-pyridin-4-yl)-2-[4-(trifluoromethoxy)phenoxy]benzamide Chemical compound C1=CNC(=O)C=C1NC(=O)C1=CC(F)=CC=C1OC1=CC=C(OC(F)(F)F)C=C1 KYRYYQRTAJIXDA-UHFFFAOYSA-N 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 125000005921 isopentoxy group Chemical group 0.000 claims 2
- INIMUMMAVCNJFA-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-2-[4-(trifluoromethoxy)phenoxy]-4-(trifluoromethyl)benzamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 INIMUMMAVCNJFA-UHFFFAOYSA-N 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 206010006074 Brachial plexus injury Diseases 0.000 claims 1
- 208000002472 Morton Neuroma Diseases 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- KXIQSNCERPESAB-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound C=1C=CC=CC=1C(=O)NC=1C=CNC(=O)C=1 KXIQSNCERPESAB-UHFFFAOYSA-N 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 58
- 238000000034 method Methods 0.000 description 10
- 238000002679 ablation Methods 0.000 description 2
- PNSVJQJVGCLXPD-UHFFFAOYSA-N CC(C)(C)c1ccc(C(NC(C=C2)=CNC2=O)=O)c(Oc2ccc(C(F)(F)F)nc2)c1 Chemical compound CC(C)(C)c1ccc(C(NC(C=C2)=CNC2=O)=O)c(Oc2ccc(C(F)(F)F)nc2)c1 PNSVJQJVGCLXPD-UHFFFAOYSA-N 0.000 description 1
- FCWGDENQRAUXMY-UHFFFAOYSA-N CC1(C)C(COc(cc(C(F)(F)F)cc2)c2C(NC(C=CN2)=CC2=O)=O)C1 Chemical compound CC1(C)C(COc(cc(C(F)(F)F)cc2)c2C(NC(C=CN2)=CC2=O)=O)C1 FCWGDENQRAUXMY-UHFFFAOYSA-N 0.000 description 1
- UEAAJOBUYFZGHL-UHFFFAOYSA-N CCCOc(cccc1)c1Oc(ccc(C(F)(F)F)c1)c1C(NC(C=CN1)=CC1=O)=O Chemical compound CCCOc(cccc1)c1Oc(ccc(C(F)(F)F)c1)c1C(NC(C=CN1)=CC1=O)=O UEAAJOBUYFZGHL-UHFFFAOYSA-N 0.000 description 1
- CGHVTPLFSBFCMC-UHFFFAOYSA-N COc(cc1)cc(Cl)c1Oc(c(C(NC(C=CN1)=CC1=O)=O)c1)ccc1F Chemical compound COc(cc1)cc(Cl)c1Oc(c(C(NC(C=CN1)=CC1=O)=O)c1)ccc1F CGHVTPLFSBFCMC-UHFFFAOYSA-N 0.000 description 1
- GGKJOYYMGVWXAT-UHFFFAOYSA-N COc(cc1)cc(F)c1Oc(cc(C(F)(F)F)cc1)c1C(NC(C=CN1)=CC1=O)=O Chemical compound COc(cc1)cc(F)c1Oc(cc(C(F)(F)F)cc1)c1C(NC(C=CN1)=CC1=O)=O GGKJOYYMGVWXAT-UHFFFAOYSA-N 0.000 description 1
- ZUFQSMFAKHTNSW-UHFFFAOYSA-N COc(ccc(Oc(cc(C(C(F)(F)F)(F)F)cc1)c1C(NC(C=CN1)=CC1=O)=O)c1)c1F Chemical compound COc(ccc(Oc(cc(C(C(F)(F)F)(F)F)cc1)c1C(NC(C=CN1)=CC1=O)=O)c1)c1F ZUFQSMFAKHTNSW-UHFFFAOYSA-N 0.000 description 1
- OMKAJNDPKOXDJE-UHFFFAOYSA-N COc(cccc1F)c1Oc(ccc(C(F)(F)F)c1)c1C(NC(C=CN1)=CC1=O)=O Chemical compound COc(cccc1F)c1Oc(ccc(C(F)(F)F)c1)c1C(NC(C=CN1)=CC1=O)=O OMKAJNDPKOXDJE-UHFFFAOYSA-N 0.000 description 1
- GOHNZFHVWZRGGX-UHFFFAOYSA-N Cc(cc(cc1)OC)c1Oc(ccc(C(F)(F)F)c1)c1C(NC(C=CN1)=CC1=O)=O Chemical compound Cc(cc(cc1)OC)c1Oc(ccc(C(F)(F)F)c1)c1C(NC(C=CN1)=CC1=O)=O GOHNZFHVWZRGGX-UHFFFAOYSA-N 0.000 description 1
- IQNGIYJIIGTIOM-UHFFFAOYSA-N Cc(cc1)ccc1Oc(c(C(NC(C=CN1)=CC1=O)=O)c1)ccc1OC(F)(F)F Chemical compound Cc(cc1)ccc1Oc(c(C(NC(C=CN1)=CC1=O)=O)c1)ccc1OC(F)(F)F IQNGIYJIIGTIOM-UHFFFAOYSA-N 0.000 description 1
- PIQAUSNVLROXMR-UHFFFAOYSA-N Cc(cccc1)c1Oc1ccc(C(F)(F)F)cc1C(NC(C=CN1)=CC1=O)=O Chemical compound Cc(cccc1)c1Oc1ccc(C(F)(F)F)cc1C(NC(C=CN1)=CC1=O)=O PIQAUSNVLROXMR-UHFFFAOYSA-N 0.000 description 1
- FNYNPPMOZIJFAC-UHFFFAOYSA-N Cc1ncccc1Oc(cc(C(F)(F)F)cc1)c1C(NC(C=CN1)=CC1=O)=O Chemical compound Cc1ncccc1Oc(cc(C(F)(F)F)cc1)c1C(NC(C=CN1)=CC1=O)=O FNYNPPMOZIJFAC-UHFFFAOYSA-N 0.000 description 1
- 101000654356 Homo sapiens Sodium channel protein type 10 subunit alpha Proteins 0.000 description 1
- FPKSPIQOEJACSE-UHFFFAOYSA-N O=C(c(c(C(F)(F)F)cc(C(F)(F)F)c1)c1Oc(c(F)c1)ccc1F)NC(C=CN1)=CC1=O Chemical compound O=C(c(c(C(F)(F)F)cc(C(F)(F)F)c1)c1Oc(c(F)c1)ccc1F)NC(C=CN1)=CC1=O FPKSPIQOEJACSE-UHFFFAOYSA-N 0.000 description 1
- CBWXHMITTMOYOY-UHFFFAOYSA-N O=C(c(cc(C(F)(F)F)cc1)c1Oc(cccc1)c1Cl)NC(C=CN1)=CC1=O Chemical compound O=C(c(cc(C(F)(F)F)cc1)c1Oc(cccc1)c1Cl)NC(C=CN1)=CC1=O CBWXHMITTMOYOY-UHFFFAOYSA-N 0.000 description 1
- XBCPDKDJZGECMM-UHFFFAOYSA-N O=C(c(cc(cc1)F)c1Oc(cc1)ccc1OCC1CC1)NC(C=CN1)=CC1=O Chemical compound O=C(c(cc(cc1)F)c1Oc(cc1)ccc1OCC1CC1)NC(C=CN1)=CC1=O XBCPDKDJZGECMM-UHFFFAOYSA-N 0.000 description 1
- DITZNZYXKSFLJE-UHFFFAOYSA-N O=C(c(ccc(C(F)(F)F)c1)c1OC1CCCCC1)NC(C=CN1)=CC1=O Chemical compound O=C(c(ccc(C(F)(F)F)c1)c1OC1CCCCC1)NC(C=CN1)=CC1=O DITZNZYXKSFLJE-UHFFFAOYSA-N 0.000 description 1
- OFVXFYHEMPXWQX-UHFFFAOYSA-N O=C(c(ccc(C(F)(F)F)c1)c1OCCCC(F)(F)F)NC(C=CN1)=CC1=O Chemical compound O=C(c(ccc(C(F)(F)F)c1)c1OCCCC(F)(F)F)NC(C=CN1)=CC1=O OFVXFYHEMPXWQX-UHFFFAOYSA-N 0.000 description 1
- REFSPUPAKCCVAD-QRUKAPELSA-N O=C(c(ccc(C(F)(F)F)c1)c1O[C@H]1C(CC2)C[C@H]2C1)NC(C=CN1)=CC1=O Chemical compound O=C(c(ccc(C(F)(F)F)c1)c1O[C@H]1C(CC2)C[C@H]2C1)NC(C=CN1)=CC1=O REFSPUPAKCCVAD-QRUKAPELSA-N 0.000 description 1
- LVBOJKUDPCHPOK-UHFFFAOYSA-N O=C(c(ccc(Cl)c1)c1OCCCC(F)(F)F)NC(C=CN1)=CC1=O Chemical compound O=C(c(ccc(Cl)c1)c1OCCCC(F)(F)F)NC(C=CN1)=CC1=O LVBOJKUDPCHPOK-UHFFFAOYSA-N 0.000 description 1
- UTKZKXRKSFATLD-UHFFFAOYSA-N O=C(c(ccc(Cl)c1)c1Oc(c(F)c1)ccc1F)NC(C=CN1)=CC1=O Chemical compound O=C(c(ccc(Cl)c1)c1Oc(c(F)c1)ccc1F)NC(C=CN1)=CC1=O UTKZKXRKSFATLD-UHFFFAOYSA-N 0.000 description 1
- ZSNOWMCACAKMOG-UHFFFAOYSA-N O=C(c(ccc(Cl)c1)c1Oc(c(F)ccc1)c1Cl)NC(C=CN1)=CC1=O Chemical compound O=C(c(ccc(Cl)c1)c1Oc(c(F)ccc1)c1Cl)NC(C=CN1)=CC1=O ZSNOWMCACAKMOG-UHFFFAOYSA-N 0.000 description 1
- VZVFDJLFHJSULP-UHFFFAOYSA-N O=C(c(ccc(Cl)c1)c1Oc(c(F)ccc1)c1F)NC(C=CN1)=CC1=O Chemical compound O=C(c(ccc(Cl)c1)c1Oc(c(F)ccc1)c1F)NC(C=CN1)=CC1=O VZVFDJLFHJSULP-UHFFFAOYSA-N 0.000 description 1
- NECWBBPMTPYKFR-UHFFFAOYSA-N O=C(c(ccc(Cl)c1)c1Oc1ccc(C(F)(F)F)nc1)NC(C=CN1)=CC1=O Chemical compound O=C(c(ccc(Cl)c1)c1Oc1ccc(C(F)(F)F)nc1)NC(C=CN1)=CC1=O NECWBBPMTPYKFR-UHFFFAOYSA-N 0.000 description 1
- XNISXOXNXGRBGI-BVUQATHDSA-N O=C(c1cc(C(F)(F)F)ccc1OC1C[C@H](C2)[C@H]2C1)NC(C=CN1)=CC1=O Chemical compound O=C(c1cc(C(F)(F)F)ccc1OC1C[C@H](C2)[C@H]2C1)NC(C=CN1)=CC1=O XNISXOXNXGRBGI-BVUQATHDSA-N 0.000 description 1
- CUVYLUQYLWTAQS-UHFFFAOYSA-N O=C(c1cc(OC(F)(F)F)ccc1OCC1CCCC1)NC(C=CN1)=CC1=O Chemical compound O=C(c1cc(OC(F)(F)F)ccc1OCC1CCCC1)NC(C=CN1)=CC1=O CUVYLUQYLWTAQS-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100031374 Sodium channel protein type 10 subunit alpha Human genes 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 210000003461 brachial plexus Anatomy 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361759059P | 2013-01-31 | 2013-01-31 | |
| US61/759,059 | 2013-01-31 | ||
| PCT/US2014/013652 WO2014120808A1 (en) | 2013-01-31 | 2014-01-29 | Pyridone amides as modulators of sodium channels |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018027902A Division JP6741704B2 (ja) | 2013-01-31 | 2018-02-20 | ナトリウムチャネルの調節剤としてのピリドンアミド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016506963A JP2016506963A (ja) | 2016-03-07 |
| JP2016506963A5 true JP2016506963A5 (OSRAM) | 2017-03-09 |
| JP6389194B2 JP6389194B2 (ja) | 2018-09-12 |
Family
ID=50073531
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015556109A Active JP6389194B2 (ja) | 2013-01-31 | 2014-01-29 | ナトリウムチャネルの調節剤としてのピリドンアミド |
| JP2018027902A Active JP6741704B2 (ja) | 2013-01-31 | 2018-02-20 | ナトリウムチャネルの調節剤としてのピリドンアミド |
| JP2019056505A Withdrawn JP2019089861A (ja) | 2013-01-31 | 2019-03-25 | ナトリウムチャネルの調節剤としてのピリドンアミド |
| JP2020169731A Pending JP2021001232A (ja) | 2013-01-31 | 2020-10-07 | ナトリウムチャネルの調節剤としてのピリドンアミド |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018027902A Active JP6741704B2 (ja) | 2013-01-31 | 2018-02-20 | ナトリウムチャネルの調節剤としてのピリドンアミド |
| JP2019056505A Withdrawn JP2019089861A (ja) | 2013-01-31 | 2019-03-25 | ナトリウムチャネルの調節剤としてのピリドンアミド |
| JP2020169731A Pending JP2021001232A (ja) | 2013-01-31 | 2020-10-07 | ナトリウムチャネルの調節剤としてのピリドンアミド |
Country Status (34)
| Country | Link |
|---|---|
| US (6) | US9051270B2 (OSRAM) |
| EP (3) | EP3239134B1 (OSRAM) |
| JP (4) | JP6389194B2 (OSRAM) |
| KR (2) | KR102295748B1 (OSRAM) |
| CN (2) | CN105026373B (OSRAM) |
| AP (1) | AP2015008633A0 (OSRAM) |
| AR (1) | AR094667A1 (OSRAM) |
| AU (3) | AU2014212509B2 (OSRAM) |
| BR (1) | BR112015018289A2 (OSRAM) |
| CA (1) | CA2898866C (OSRAM) |
| CL (1) | CL2015002147A1 (OSRAM) |
| CY (1) | CY1119163T1 (OSRAM) |
| DK (2) | DK2953931T3 (OSRAM) |
| ES (2) | ES2857687T3 (OSRAM) |
| GE (2) | GEP20217286B (OSRAM) |
| HR (2) | HRP20170787T1 (OSRAM) |
| HU (2) | HUE033370T2 (OSRAM) |
| IL (2) | IL269964B1 (OSRAM) |
| LT (2) | LT2953931T (OSRAM) |
| MX (2) | MX2021003687A (OSRAM) |
| NZ (2) | NZ710270A (OSRAM) |
| PE (2) | PE20151781A1 (OSRAM) |
| PH (1) | PH12015501661B1 (OSRAM) |
| PL (2) | PL3239134T3 (OSRAM) |
| PT (2) | PT2953931T (OSRAM) |
| RS (2) | RS56015B1 (OSRAM) |
| RU (1) | RU2662223C2 (OSRAM) |
| SG (2) | SG11201505953TA (OSRAM) |
| SI (2) | SI2953931T1 (OSRAM) |
| SM (2) | SMT201700256T1 (OSRAM) |
| TW (2) | TWI714967B (OSRAM) |
| UA (1) | UA120589C2 (OSRAM) |
| UY (1) | UY35288A (OSRAM) |
| WO (1) | WO2014120808A1 (OSRAM) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2014121983A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств |
| US9630929B2 (en) | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| US8952169B2 (en) | 2012-05-22 | 2015-02-10 | Xenon Pharmaceuticals Inc. | N-substituted benzamides and methods of use thereof |
| CN104797555B (zh) | 2012-07-06 | 2017-12-22 | 基因泰克公司 | N‑取代的苯甲酰胺及其使用方法 |
| KR102295748B1 (ko) * | 2013-01-31 | 2021-09-01 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 피리돈 아미드 |
| EP2951168B1 (en) | 2013-01-31 | 2017-01-04 | Vertex Pharmaceuticals Incorporated | Quinoline and quinoxaline amides as modulators of sodium channels |
| HK1213476A1 (zh) | 2013-03-14 | 2016-07-08 | 基因泰克公司 | 取代的三唑並吡啶及其使用方法 |
| CA2898680A1 (en) | 2013-03-15 | 2014-09-18 | Genentech,Inc. | Substituted benzoxazoles and methods of use thereof |
| JP6337109B2 (ja) | 2013-07-19 | 2018-06-06 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ナトリウムチャネルの調節剤としてのスルホンアミド |
| CA2931732A1 (en) | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| TWI703154B (zh) | 2013-12-13 | 2020-09-01 | 美商維泰克斯製藥公司 | 作為鈉通道調節劑之吡啶酮醯胺之前藥 |
| WO2016007534A1 (en) | 2014-07-07 | 2016-01-14 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| PE20180575A1 (es) | 2015-05-22 | 2018-04-04 | Genentech Inc | Benzamidas sustituidas y metodos para utilizarlas |
| MA42683A (fr) | 2015-08-27 | 2018-07-04 | Genentech Inc | Composés thérapeutiques et leurs méthodes utilisation |
| BR112018006189A2 (pt) | 2015-09-28 | 2018-10-09 | Genentech Inc | compostos da fórmula, composição farmacêutica, métodos de tratamento de uma doença, de diminuição do fluxo de íons e de tratamento de prurido em um mamífero, método para tratamento de dores em um mamífero e uso de um composto |
| JP2018535234A (ja) | 2015-11-25 | 2018-11-29 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル遮断薬として有用な置換ベンズアミド |
| CN109153647A (zh) | 2016-02-15 | 2019-01-04 | 分子医学研究中心责任有限公司 | 用于治疗癌症的taf1抑制剂 |
| WO2017147147A1 (en) * | 2016-02-23 | 2017-08-31 | PixarBio Corporation | Compositions comprising nav1.7 selective inhibitors for treating acute, post-operative, or chronic pain and methods of using the same |
| CN109071426A (zh) | 2016-03-30 | 2018-12-21 | 基因泰克公司 | 取代的苯甲酰胺及其使用方法 |
| WO2018072602A1 (en) | 2016-10-17 | 2018-04-26 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| JP2020511511A (ja) | 2017-03-24 | 2020-04-16 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体 |
| UA124857C2 (uk) | 2017-05-16 | 2021-12-01 | Вертекс Фармасьютикалз Інкорпорейтед | Дейтеровані піридонаміди і їх проліки як модулятори натрієвих каналів |
| UY37806A (es) | 2017-07-11 | 2020-01-31 | Vertex Pharma | Carboxamidas como moduladores de los canales de sodio |
| EP3752152A1 (en) | 2018-02-12 | 2020-12-23 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
| EP3759098A1 (en) | 2018-02-26 | 2021-01-06 | Genentech, Inc. | Pyridine-sulfonamide compounds and their use against pain and related conditions |
| US10947251B2 (en) | 2018-03-30 | 2021-03-16 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| KR102812202B1 (ko) | 2018-11-02 | 2025-05-23 | 머크 샤프 앤드 돔 엘엘씨 | Nav1.8 억제제로서의 2-아미노-n-헤테로아릴-니코틴아미드 |
| EP3873468A4 (en) | 2018-11-02 | 2022-10-26 | Merck Sharp & Dohme LLC | 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS |
| EP3907218A4 (en) * | 2019-01-04 | 2022-09-21 | Jiangsu Hengrui Medicine Co., Ltd. | 6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, METHOD FOR PREPARATION AND MEDICAL USE |
| US12441703B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| WO2020151728A1 (zh) * | 2019-01-25 | 2020-07-30 | 江苏恒瑞医药股份有限公司 | 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
| BR112021014178A2 (pt) * | 2019-02-20 | 2021-09-21 | Jiangsu Hengrui Medicine Co., Ltd. | Derivado de pró-fármaco de 6-oxo-1,6-diidropiridazina, método de preparação para o mesmo e aplicação do mesmo na medicina |
| WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
| WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| WO2021018165A1 (zh) * | 2019-07-30 | 2021-02-04 | 江苏恒瑞医药股份有限公司 | 吡啶苯甲酰胺类衍生物、其制备方法及其在医药上的应用 |
| CN112390745B (zh) * | 2019-08-19 | 2022-10-21 | 江苏恒瑞医药股份有限公司 | 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用 |
| WO2021032074A1 (zh) * | 2019-08-19 | 2021-02-25 | 江苏恒瑞医药股份有限公司 | 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用 |
| CA3150400A1 (en) * | 2019-09-12 | 2021-03-18 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Pyridine oxynitride, preparation method therefor and use thereof |
| HUE069128T2 (hu) | 2019-12-06 | 2025-02-28 | Vertex Pharma | Szubsztituált tetrahidrofurán vegyületek mint nátriumcsatornák modulátorai |
| CN113045487B (zh) * | 2019-12-27 | 2025-01-17 | 明慧医药（上海）有限公司 | 一种选择性钠通道调节剂及其制备和应用 |
| CN114437062B (zh) * | 2020-04-30 | 2024-05-17 | 成都海博为药业有限公司 | 一种可作为钠通道调节剂的化合物及其用途 |
| JP7323723B2 (ja) | 2020-06-17 | 2023-08-08 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｎａｖ１．８阻害剤としての２－オキソイミダゾリジン－４－カルボキサミド |
| CN113880771B (zh) * | 2020-07-03 | 2023-09-19 | 福建盛迪医药有限公司 | 一种选择性Nav抑制剂的结晶形式及其制备方法 |
| CN111808019B (zh) * | 2020-09-08 | 2020-11-27 | 上海济煜医药科技有限公司 | 一种并环化合物及其应用 |
| CN114031518B (zh) | 2020-12-08 | 2023-08-18 | 成都海博为药业有限公司 | 一种苄胺或苄醇衍生物及其用途 |
| KR20240005878A (ko) | 2021-05-07 | 2024-01-12 | 머크 샤프 앤드 돔 엘엘씨 | Nav1.8 억제제로서의 시클로알킬 3-옥소피페라진 카르복스아미드 및 시클로헤테로알킬 3-옥소피페라진 카르복스아미드 |
| US20240285596A1 (en) | 2021-06-04 | 2024-08-29 | Vertex Pharmaceuticals Incorporated | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
| US20240368135A1 (en) | 2021-06-04 | 2024-11-07 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| US20240400544A1 (en) | 2021-06-04 | 2024-12-05 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| AU2022284886A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
| CN117794918A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | 经取代的四氢呋喃类似物作为钠通道调节剂 |
| US20240294512A1 (en) | 2021-06-04 | 2024-09-05 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| UY39882A (es) | 2021-08-02 | 2023-06-15 | Eurofarma Laboratorios S A | COMPUESTOS NACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
| UY39881A (es) | 2021-08-02 | 2023-06-15 | Eurofarma Laboratorios S A | “COMPUESTOS N-ACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS” |
| WO2023160509A1 (zh) * | 2022-02-25 | 2023-08-31 | 中国科学院上海药物研究所 | 脒类衍生化合物及其制备方法和用途 |
| TW202404969A (zh) | 2022-04-22 | 2024-02-01 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| CN119522214A (zh) | 2022-04-22 | 2025-02-25 | 沃泰克斯药物股份有限公司 | 用于治疗疼痛的杂芳基化合物 |
| AU2023255558A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| JP2025513454A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| WO2023211990A1 (en) | 2022-04-25 | 2023-11-02 | Siteone Therapeutics, Inc. | Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain |
| WO2023207949A1 (zh) * | 2022-04-25 | 2023-11-02 | 中国科学院上海药物研究所 | 并环类化合物及其应用 |
| KR20250120351A (ko) | 2022-12-06 | 2025-08-08 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 치환된 테트라하이드로푸란 조절제의 합성을 위한 방법 |
| EP4660182A1 (en) | 2023-01-30 | 2025-12-10 | Eurofarma Laboratórios S.A. | Nav1.7- and/or nav1.8-inhibiting aryl pyridine compounds, processes for the preparation thereof, compositions, uses, methods for treatment using same, and kits |
| AR131715A1 (es) | 2023-01-30 | 2025-04-23 | Eurofarma Laboratorios S A | AMIDAS BLOQUEADORAS DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y KITS |
| WO2024159287A1 (pt) | 2023-01-30 | 2024-08-08 | Eurofarma Laboratórios S.A. | Hidroxamatos bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits |
| AR131690A1 (es) | 2023-01-30 | 2025-04-23 | Eurofarma Laboratorios S A | COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y LOS KITS |
| AR131658A1 (es) | 2023-01-30 | 2025-04-16 | Eurofarma Laboratorios S A | Hidrazidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y sus kits |
| AU2024257755A1 (en) | 2023-04-19 | 2025-11-13 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Nav1.8 inhibitors, preparation method therefor and use thereof |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| TW202523313A (zh) | 2023-10-23 | 2025-06-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
| WO2025160286A1 (en) | 2024-01-24 | 2025-07-31 | Siteone Therapeutics, Inc. | 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH598252A5 (OSRAM) * | 1974-01-04 | 1978-04-28 | Hoffmann La Roche | |
| GB1447583A (en) * | 1974-02-04 | 1976-08-25 | Ici Ltd | Xanthene derivatives |
| US4086350A (en) * | 1974-11-06 | 1978-04-25 | Smithkline Corporation | Pharmaceutical compositions and method of producing anti-psychotic activity without extrapyramidal symptoms |
| GB1543964A (en) * | 1976-04-08 | 1979-04-11 | Ici Ltd | Method of antagonising herbicides on soyabean and cotton |
| US5281620A (en) * | 1986-12-23 | 1994-01-25 | Cancer Research Campaign Technology Limited | Compounds having antitumor and antibacterial properties |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| JP3285391B2 (ja) * | 1992-09-01 | 2002-05-27 | 日本化学工業株式会社 | ２−フェノキシ安息香酸の製造法 |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| AU7712000A (en) | 1999-09-24 | 2001-04-24 | Johns Hopkins University School Of Medicine, The | Methods for identifying an agent that corrects defective protein folding |
| JP2003034671A (ja) * | 2001-05-17 | 2003-02-07 | Nippon Nohyaku Co Ltd | ベンズアミド誘導体及び農園芸用薬剤並びにその使用方法 |
| AP1822A (en) * | 2002-02-14 | 2008-01-30 | Pharmacia Corp | Substituted pyridinones as modulators of P38 MAP kinase. |
| KR20060073930A (ko) * | 2003-08-08 | 2006-06-29 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체 |
| AP2006003534A0 (en) * | 2003-09-03 | 2006-04-30 | Pfizer | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists. |
| AU2005266090A1 (en) | 2004-07-23 | 2006-02-02 | Pfizer Inc. | Pyridine derivatives |
| KR20080019693A (ko) | 2005-06-09 | 2008-03-04 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널 조절인자로서의 인단 유도체 |
| RU2008113836A (ru) | 2005-09-09 | 2009-10-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Бициклические производные в качестве модуляторов потенциалозависимых ионных каналов |
| CA2624831A1 (en) | 2005-10-12 | 2007-04-26 | Vertex Pharmaceuticals Incorporated | Biphenyl derivatives as modulators of voltage gated ion channels |
| US8841483B2 (en) * | 2006-04-11 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of voltage-gated sodium channels |
| BRPI0810202A2 (pt) * | 2007-05-03 | 2014-10-21 | Pfizer Ltd | Derivados de piridina |
| US8193194B2 (en) | 2007-05-25 | 2012-06-05 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| NZ584474A (en) * | 2007-10-11 | 2012-06-29 | Vertex Pharma | Amides useful as inhibitors of voltage-gated sodium channels |
| US8519137B2 (en) | 2007-10-11 | 2013-08-27 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| AU2008310663A1 (en) | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Aryl amides useful as inhibitors of voltage-gated sodium channels |
| WO2009058299A1 (en) * | 2007-10-31 | 2009-05-07 | Merck & Co., Inc. | P2x3 receptor antagonists for treatment of pain |
| CN102264722B (zh) | 2008-12-23 | 2014-04-02 | 霍夫曼-拉罗奇有限公司 | 作为p2x7调节剂的二氢吡啶酮酰胺 |
| CN105254557A (zh) * | 2009-05-29 | 2016-01-20 | 拉夸里亚创药株式会社 | 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物 |
| TW201103904A (en) * | 2009-06-11 | 2011-02-01 | Hoffmann La Roche | Janus kinase inhibitor compounds and methods |
| CA2791281A1 (en) * | 2010-03-15 | 2011-09-22 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta-secretase modulators |
| CA2812526A1 (en) | 2010-05-06 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| WO2012050918A2 (en) * | 2010-09-29 | 2012-04-19 | Presidio Pharmaceutical, Inc. | Tricyclic fused ring inhibitors of hepatitis c |
| DK2670752T3 (en) | 2011-02-02 | 2016-07-04 | Vertex Pharma | PYRROLOPYRAZINE SPIROCYCLIC PIPERIDINAMIDE AS ION CHANNEL MODULATORS |
| US8962859B2 (en) * | 2011-02-15 | 2015-02-24 | Amgen Inc. | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use |
| WO2012112743A1 (en) | 2011-02-18 | 2012-08-23 | Vertex Pharmaceuticals Incorporated | Chroman - spirocyclic piperidine amides as modulators of ion channels |
| EP2686325B1 (en) | 2011-03-14 | 2016-12-14 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| WO2012122716A1 (en) * | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases |
| EA025572B1 (ru) * | 2011-03-29 | 2017-01-30 | Санофи | Лекарственные формы отамиксабана с улучшенной стабильностью |
| WO2013021535A1 (ja) | 2011-08-10 | 2013-02-14 | 三菱電機株式会社 | 誘導加熱調理器及びそのプログラム |
| CN102584774B (zh) * | 2011-12-22 | 2014-08-06 | 合肥工业大学 | 一种呫吨酮类衍生物及其用途 |
| ES2621220T3 (es) | 2012-03-06 | 2017-07-03 | Pfizer Inc. | Derivados macrocíclicos para el tratamiento de enfermedades proliferativas |
| CN102659628B (zh) * | 2012-04-26 | 2014-07-02 | 四川大学 | 含芳酰胺的邻苯二甲腈单体及其合成方法和用其固化制备的聚邻苯二甲腈树脂 |
| EP2951168B1 (en) | 2013-01-31 | 2017-01-04 | Vertex Pharmaceuticals Incorporated | Quinoline and quinoxaline amides as modulators of sodium channels |
| EP2951155B1 (en) | 2013-01-31 | 2019-06-19 | Vertex Pharmaceuticals Incorporated | Amides as modulators of sodium channels |
| KR102295748B1 (ko) | 2013-01-31 | 2021-09-01 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 피리돈 아미드 |
| TWI606048B (zh) | 2013-01-31 | 2017-11-21 | 帝人製藥股份有限公司 | 唑苯衍生物 |
| JP6337109B2 (ja) | 2013-07-19 | 2018-06-06 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ナトリウムチャネルの調節剤としてのスルホンアミド |
| TWI703154B (zh) | 2013-12-13 | 2020-09-01 | 美商維泰克斯製藥公司 | 作為鈉通道調節劑之吡啶酮醯胺之前藥 |
| UY37806A (es) | 2017-07-11 | 2020-01-31 | Vertex Pharma | Carboxamidas como moduladores de los canales de sodio |
| EP3752152A1 (en) | 2018-02-12 | 2020-12-23 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
-
2014
- 2014-01-29 KR KR1020217007028A patent/KR102295748B1/ko active Active
- 2014-01-29 DK DK14704053.9T patent/DK2953931T3/en active
- 2014-01-29 NZ NZ710270A patent/NZ710270A/en unknown
- 2014-01-29 HU HUE14704053A patent/HUE033370T2/en unknown
- 2014-01-29 GE GEAP201413922A patent/GEP20217286B/en unknown
- 2014-01-29 UY UY0001035288A patent/UY35288A/es active IP Right Grant
- 2014-01-29 LT LTEP14704053.9T patent/LT2953931T/lt unknown
- 2014-01-29 IL IL269964A patent/IL269964B1/en unknown
- 2014-01-29 AR ARP140100281A patent/AR094667A1/es active IP Right Grant
- 2014-01-29 JP JP2015556109A patent/JP6389194B2/ja active Active
- 2014-01-29 AP AP2015008633A patent/AP2015008633A0/xx unknown
- 2014-01-29 TW TW108105717A patent/TWI714967B/zh active
- 2014-01-29 GE GEAP201414909A patent/GEP20207177B/en unknown
- 2014-01-29 SI SI201430220T patent/SI2953931T1/sl unknown
- 2014-01-29 CN CN201480011392.XA patent/CN105026373B/zh active Active
- 2014-01-29 PT PT147040539T patent/PT2953931T/pt unknown
- 2014-01-29 UA UAA201508443A patent/UA120589C2/uk unknown
- 2014-01-29 CN CN201810153601.4A patent/CN108164457B/zh active Active
- 2014-01-29 PL PL17152492T patent/PL3239134T3/pl unknown
- 2014-01-29 RS RS20170516A patent/RS56015B1/sr unknown
- 2014-01-29 HU HUE17152492A patent/HUE053448T2/hu unknown
- 2014-01-29 ES ES17152492T patent/ES2857687T3/es active Active
- 2014-01-29 PL PL14704053T patent/PL2953931T3/pl unknown
- 2014-01-29 MX MX2021003687A patent/MX2021003687A/es unknown
- 2014-01-29 RU RU2015136795A patent/RU2662223C2/ru active
- 2014-01-29 PE PE2015001572A patent/PE20151781A1/es active IP Right Grant
- 2014-01-29 WO PCT/US2014/013652 patent/WO2014120808A1/en not_active Ceased
- 2014-01-29 PE PE2019001687A patent/PE20191495A1/es unknown
- 2014-01-29 CA CA2898866A patent/CA2898866C/en active Active
- 2014-01-29 EP EP17152492.9A patent/EP3239134B1/en active Active
- 2014-01-29 RS RS20210235A patent/RS61503B1/sr unknown
- 2014-01-29 ES ES14704053T patent/ES2626555T3/es active Active
- 2014-01-29 NZ NZ750187A patent/NZ750187A/en unknown
- 2014-01-29 KR KR1020157023601A patent/KR102227592B1/ko active Active
- 2014-01-29 EP EP20216557.7A patent/EP3865475A1/en active Pending
- 2014-01-29 DK DK17152492.9T patent/DK3239134T3/da active
- 2014-01-29 SM SM20170256T patent/SMT201700256T1/it unknown
- 2014-01-29 LT LTEP17152492.9T patent/LT3239134T/lt unknown
- 2014-01-29 SM SM20210030T patent/SMT202100030T1/it unknown
- 2014-01-29 PT PT171524929T patent/PT3239134T/pt unknown
- 2014-01-29 SI SI201431756T patent/SI3239134T1/sl unknown
- 2014-01-29 TW TW103103691A patent/TWI655187B/zh active
- 2014-01-29 AU AU2014212509A patent/AU2014212509B2/en active Active
- 2014-01-29 SG SG11201505953TA patent/SG11201505953TA/en unknown
- 2014-01-29 SG SG10201706206PA patent/SG10201706206PA/en unknown
- 2014-01-29 US US14/167,759 patent/US9051270B2/en active Active
- 2014-01-29 MX MX2015009602A patent/MX383688B/es unknown
- 2014-01-29 HR HRP20170787TT patent/HRP20170787T1/hr unknown
- 2014-01-29 BR BR112015018289A patent/BR112015018289A2/pt not_active Application Discontinuation
- 2014-01-29 EP EP14704053.9A patent/EP2953931B1/en active Active
-
2015
- 2015-04-29 US US14/699,437 patent/US9393235B2/en active Active
- 2015-07-27 PH PH12015501661A patent/PH12015501661B1/en unknown
- 2015-07-28 IL IL24019515A patent/IL240195B/en active IP Right Grant
- 2015-07-31 CL CL2015002147A patent/CL2015002147A1/es unknown
-
2016
- 2016-06-06 US US15/174,896 patent/US9758483B2/en active Active
-
2017
- 2017-05-31 CY CY20171100560T patent/CY1119163T1/el unknown
- 2017-08-03 US US15/667,722 patent/US10087143B2/en active Active
-
2018
- 2018-02-20 JP JP2018027902A patent/JP6741704B2/ja active Active
- 2018-08-09 AU AU2018214105A patent/AU2018214105B9/en active Active
- 2018-08-21 US US16/107,109 patent/US10738009B2/en active Active
-
2019
- 2019-03-25 JP JP2019056505A patent/JP2019089861A/ja not_active Withdrawn
-
2020
- 2020-06-24 US US16/910,965 patent/US11673864B2/en active Active
- 2020-07-02 AU AU2020204425A patent/AU2020204425A1/en not_active Abandoned
- 2020-10-07 JP JP2020169731A patent/JP2021001232A/ja active Pending
-
2021
- 2021-03-01 HR HRP20210349TT patent/HRP20210349T1/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506963A5 (OSRAM) | ||
| HRP20210349T1 (hr) | Piridon amidi kao modulatori natrijevih kanala | |
| JP2016508500A5 (OSRAM) | ||
| JP2016525122A5 (OSRAM) | ||
| RU2016105511A (ru) | Сульфонамиды в качестве молдуляторов натриевых каналов | |
| RU2015136779A (ru) | Амиды в качестве модуляторов натриевых каналов | |
| RU2015136770A (ru) | Хинолинамиды и хиназолинамиды в качестве модуляторов натриевых каналов | |
| JP2018517746A5 (OSRAM) | ||
| JP2020526561A5 (OSRAM) | ||
| JP2014511892A5 (OSRAM) | ||
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| JP2008510714A5 (OSRAM) | ||
| CA2601508A1 (en) | Cyclopropanecarboxamide derivatives | |
| RU2018104868A (ru) | 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 | |
| JP2019517487A5 (OSRAM) | ||
| JP2009542717A5 (OSRAM) | ||
| JP5911929B2 (ja) | 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 | |
| RU2017116197A (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера | |
| RU2011121567A (ru) | Изоиндолиновые соединения для применения при лечении рака | |
| FI3988117T3 (fi) | Terapeuttiset vasta-aineet ja niiden käyttö | |
| JP2015526441A5 (OSRAM) | ||
| RU2012152639A (ru) | Пиколинамидные и пиримидин-4-карбоксамидные соединения, способ их получения и фармацевтическая композиция, включающая их | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| RU2015113746A (ru) | Замещенные сульфонамиды | |
| EA016687B8 (ru) | Производные циклопропиламида |